S2k-Leitlinie nicht alkoholische Fettlebererkrankungen

A Methodik

^* Diese Autoren sind gleichberechtigt. AG-Leiter 3 – 17 in alphabetischer Reihenfolge.

^# Für die Autoren des DGVS Leitlinien-Komitees.

• Literatur

• 1 Schwimmer JB, Deutsch R, Kahen T et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393
• 2 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690
• 3 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6: 263-273
• 4 Mensink GB, Schienkiewitz A, Haftenberger M et al. Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 786-794
• 5 Kurth BM, Schaffrath RA. The prevalence of overweight and obese children and adolescents living in Germany. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 736-743
• 6 Gombet T, Longo-Mbenza B, Ellenga-Mbolla B et al. Aging, female sex, migration, elevated HDL-C, and inflammation are associated with prevalence of metabolic syndrome among African bank employees. Int J Gen Med 2012; 5: 495-503
• 7 Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 162-168
• 8 Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609
• 9 Loria P, Adinolfi LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010; 42: 272-282
• 10 Fan JG, Jia JD, Li YM et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis 2011; 12: 38-44
• 11 http://www.worldgastroenterology.org/assets/export/userfiles/2012_NASH%20and%20NAFLD_Final_long.pdf
• 12 Farrell GC, Chitturi S, Lau GK et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007; 22: 775-777
• 13 Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384
• 14 Tannapfel A, Denk H, Dienes HP et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 2011; 458: 511-523
• 15 Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147: 754-764
• 16 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-1391
• 17 Brunt EM, Neuschwander-Tetri BA, Oliver D et al. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004; 35: 1070-1082
• 18 Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71
• 19 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005; 22: 330-338
• 20 Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321
• 21 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725
• 22 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-1846
• 23 Brunt EM. Non-alcoholic fatty liver disease: what's new under the microscope?. Gut 2011; 60: 1152-1158
• 24 Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
• 25 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059-1062
• 26 Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
• 27 Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218
• 28 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285
• 29 Vos B, Moreno C, Nagy N et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011; 74: 389-394
• 30 Younossi ZM, Stepanova M, Negro F et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012; 91: 319-327
• 31 Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701
• 32 Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41
• 33 Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012; 5: 199-207
• 34 Poordad FF. Nonalcoholic fatty liver disease: a review. Expert Opin Emerg Drugs 2005; 10: 661-670
• 35 Musso G, Gambino R, Cassader M et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649
• 36 Gawrieh S, Chalasani N. NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials?. Gastroenterology 2013; 145: 717-719
• 37 Vigano L, Ravarino N, Ferrero A et al. Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. Arch Surg 2012; 147: 1085-1091
• 38 Tannapfel A, Geissler F, Witzigmann H et al. Analysis of liver allograft rejection related genes using cDNA-microarrays in liver allograft specimen. Transplant Proc 2001; 33: 3283-3284
• 39 Gentilucci UV, Santini D, Vincenzi B et al. Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol 2006; 24: 5467-5468
• 40 Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007; 86: 285-300
• 41 Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990
• 42 Nordlinger B, Van Cutsem E, Rougier P et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045
• 43 Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072
• 44 Nakano H, Oussoultzoglou E, Rosso E et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247: 118-124
• 45 Lee JY, Kim KM, Lee SG et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239-244
• 46 Marcos A, Fisher RA, Ham JM et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 2000; 69: 1375-1379
• 47 Bohte AE, van Werven JR, Bipat S et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 2011; 21: 87-97
• 48 Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45
• 49 Speliotes EK, Yerges-Armstrong LM, Wu J et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324
• 50 Neuschwander-Tetri BA, Clark JM, Bass NM et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52: 913-924
• 51 Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58: 593-608
• 52 Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395
• 53 Das K, Das K, Mukherjee PS et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010; 51: 1593-1602
• 54 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6: 274-283
• 55 Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131
• 56 Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-1110
• 57 Minervini MI, Ruppert K, Fontes P et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009; 50: 501-510
• 58 Zhou YJ, Li YY, Nie YQ et al. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012; 13: 153-160
• 59 Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012; 18: 29-37
• 60 Charlton MR, Burns JM, Pedersen RA et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-1253
• 61 Kemmer N, Neff GW, Franco E et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 2013; 96: 860-862
• 62 Singal AK, Guturu P, Hmoud B et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95: 755-760
• 63 O'Leary JG, Landaverde C, Jennings L et al. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011; 9: 700-704
• 64 Park CW, Tsai NT, Wong LL. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 2011; 25: E606-E611
• 65 Nayak NC, Jain D, Vasdev N et al. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. Eur J Gastroenterol Hepatol 2012; 24: 1199-1208
• 66 Marmur J, Bergquist A, Stal P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand J Gastroenterol 2010; 45: 60-69
• 67 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U. S. Hepatology 2014; 59: 2188-2195
• 68 Schutte K, Kipper M, Kahl S et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion 2013; 87: 147-159
• 69 Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128
• 70 Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223
• 71 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350
• 72 http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/WS0100/_XWD_PROC?_XWD_102/1/XWD_CUBE.DRILL/_XWD_130/D.946/14499
• 73 Davis GL, Roberts WL. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep 2010; 12: 1-6
• 74 Baumeister SE, Volzke H, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134: 85-94
• 75 Park HS, Han JH, Choi KM et al. Relation between elevated serum alanine aminotransferase and metabolic syndrome in Korean adolescents. Am J Clin Nutr 2005; 82: 1046-1051
• 76 Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007–2010. J Pediatr 2013; 162: 496-500
• 77 Gerber L, Otgonsuren M, Mishra A et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 2012; 36: 772-781
• 78 Oddy WH, Herbison CE, Jacoby P et al. The Western dietary pattern is prospectively associated with nonalcoholic fatty liver disease in adolescence. Am J Gastroenterol 2013; 108: 778-785
• 79 Abid A, Taha O, Nseir W et al. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009; 51: 918-924
• 80 Ayonrinde OT, Olynyk JK, Beilin LJ et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800-809
• 81 Benhamed F, Denechaud PD, Lemoine M et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest 2012; 122: 2176-2194
• 82 Lallukka S, Sevastianova K, Perttila J et al. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013; 56: 886-892
• 83 Eliades M, Spyrou E, Agrawal N et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013; 38: 246-254
• 84 Targher G, Bertolini L, Scala L et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-524
• 85 Kwok RM, Torres DM, Harrison SA. Vitamin D and nonalcoholic fatty liver disease (NAFLD): is it more than just an association?. Hepatology 2013; 58: 1166-1174
• 86 Mouzaki M, Comelli EM, Arendt BM et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013; 58: 120-127
• 87 Jumpertz R, Le DS, Turnbaugh PJ et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65
• 88 Raman M, Ahmed I, Gillevet PM et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11: 868-875
• 89 Volynets V, Kuper MA, Strahl S et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 2012; 57: 1932-1941
• 90 Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601-609
• 91 Loomba R, Abraham M, Unalp A et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-951
• 92 Angulo P, Bugianesi E, Bjornsson ES et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789
• 93 Al-Serri A, Anstee QM, Valenti L et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol 2012; 56: 448-454
• 94 Ferreira DM, Castro RE, Machado MV et al. Apoptosis and insulin resistance in liver and peripheral tissues of morbidly obese patients is associated with different stages of non-alcoholic fatty liver disease. Diabetologia 2011; 54: 1788-1798
• 95 Ahmed A, Rabbitt E, Brady T et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 2012; 7: e29531
• 96 Lake AD, Novak P, Shipkova P et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol 2013; 268: 132-140
• 97 Asanuma T, Ono M, Kubota K et al. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 2010; 59: 258-266
• 98 Catalan V, Gomez-Ambrosi J, Rodriguez A et al. Increased tenascin C and Toll-like receptor 4 levels in visceral adipose tissue as a link between inflammation and extracellular matrix remodeling in obesity. J Clin Endocrinol Metab 2012; 97: E1880-E1889
• 99 Ferreyra Solari NE, Inzaugarat ME, Baz P et al. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol 2012; 32: 611-621
• 100 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; 28 (Suppl. 01) 68-76
• 101 Schwimmer JB, Celedon MA, Lavine JE et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585-1592
• 102 Makkonen J, Pietilainen KH, Rissanen A et al. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. J Hepatol 2009; 50: 1035-1042
• 103 Bambha K, Belt P, Abraham M et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55: 769-780
• 104 Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 645-655
• 105 Romeo S, Kozlitina J, Xing C et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465
• 106 Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894
• 107 Stickel F, Buch S, Lau K et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95
• 108 Trepo E, Pradat P, Potthoff A et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011; 54: 60-69
• 109 Speliotes EK, Butler JL, Palmer CD et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904-912
• 110 Kozlitina J, Smagris E, Stender S et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46: 352-356
• 111 Liu YL, Reeves HL, Burt AD et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5: 4309
• 112 Bae JC, Suh S, Park SE et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 2012; 7: e46819
• 113 Da Silva HE, Arendt BM, Noureldin SA et al. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet 2014; 114: 1181-1194
• 114 Hsieh S, Klassen AC, Curriero FC et al. Fast-food restaurants, park access, and insulin resistance among Hispanic youth. Am J Prev Med 2014; 46: 378-387
• 115 Kantartzis K, Thamer C, Peter A et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009; 58: 1281-1288
• 116 Sathiaraj E, Chutke M, Reddy MY et al. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. Eur J Clin Nutr 2011; 65: 533-537
• 117 Shi L, Liu ZW, Li Y et al. The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu. Biomed Environ Sci 2012; 25: 383-391
• 118 Hashemi KA, Alavian SM, Haghighatdoost F et al. Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents. Hepat Mon 2014; 14: e10939
• 119 Stanhope KL, Schwarz JM, Keim NL et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334
• 120 Molloy JW, Calcagno CJ, Williams CD et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012; 55: 429-436
• 121 Zelber-Sagi S, Lotan R, Shlomai A et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56: 1145-1151
• 122 Wong VW, Wong GL, Choi PC et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974
• 123 Koehler EM, Schouten JN, Hansen BE et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012; 57: 1305-1311
• 124 Wang Z, Xu M, Peng J et al. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Exp Gerontol 2013; 48: 705-709
• 125 Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-650
• 126 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1155-1161
• 127 Musso G, Cassader M, De Michieli F et al. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012; 56: 933-942
• 128 Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359-404
• 129 Stefan N, Haring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 2013; 19: 394-395
• 130 Stefan N, Haring HU. The role of hepatokines in metabolism. Nat Rev Endocrinol 2013; 9: 144-152
• 131 Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530
• 132 Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362
• 133 Park SK, Seo MH, Shin HC et al. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57: 1378-1383
• 134 Bae JC, Rhee EJ, Lee WY et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011; 34: 727-729
• 135 Adams LA, Harmsen S, St Sauver JL et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010; 105: 1567-1573
• 136 Adams LA, Lymp JF, St SJ et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121
• 137 Naik A, Kosir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics 2013; 102: 84-95
• 138 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359
• 139 Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-665
• 140 Ertle J, Dechene A, Sowa JP et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443
• 141 Nkontchou G, Tran Van NJ, Ziol M et al. Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. Eur J Gastroenterol Hepatol 2013; 25: 94-98
• 142 Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-1307
• 143 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatol Res 2012; 42: 1-14
• 144 Kawada N, Imanaka K, Kawaguchi T et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-1194
• 145 Yatsuji S, Hashimoto E, Tobari M et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254
• 146 Bhala N, Angulo P, van der Poorten D et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216
• 147 Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978
• 148 Yu J, Shen J, Sun TT et al. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 2013; 23: 483-491
• 149 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-1832
• 150 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
• 151 El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380
• 152 Jee SH, Ohrr H, Sull JW et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202
• 153 Nair S, Mason A, Eason J et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 2002; 36: 150-155
• 154 Sorrentino P, D'Angelo S, Ferbo U et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009; 50: 351-357
• 155 Tokushige K, Hashimoto E, Kodama K. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. J Gastroenterol Hepatol 2013; 28 (Suppl. 04) 88-92
• 156 Zein CO, Unalp A, Colvin R et al. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 753-759
• 157 Weingarten TN, Swain JM, Kendrick ML et al. Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery. Obes Surg 2011; 21: 1714-1720
• 158 Ribeireiro T, Swain J, Sarr M et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery – a prospective analysis. Obes Surg 2011; 21: 310-315
• 159 Rebibo L, Gerin O, Verhaeghe P et al. Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: a case-matched study. Surg Obes Relat Dis 2014; 10: 405-410
• 160 Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford) 2011; 13: 846-859
• 161 Cauchy F, Zalinski S, Dokmak S et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013; 100: 113-121
• 162 Tannapfel A, Reinacher-Schick A. Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC). Z Gastroenterol 2008; 46: 435-440
• 163 Tannapfel A, Denk H, Dienes HP et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines. Pathologe 2010; 31: 225-237
• 164 Miyake K, Hayakawa K, Nishino M et al. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12: 722-727
• 165 Peppercorn PD, Reznek RH, Wilson P et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77: 2008-2011
• 166 Sorensen P, Edal AL, Madsen EL et al. Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil. Cancer 1995; 75: 2592-2596
• 167 Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137-144
• 168 Reddy SK, Reilly C, Zhan M et al. Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis. Med Oncol 2014; 31: 971
• 169 Makowiec F, Mohrle S, Neeff H et al. Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases. J Gastrointest Surg 2011; 15: 153-164
• 170 Pawlik TM, Olino K, Gleisner AL et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868
• 171 Reissfelder C, Brand K, Sobiegalla J et al. Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery 2014; 155: 245-254
• 172 Wolf PS, Park JO, Bao F et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg 2013; 216: 41-49
• 173 Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200: 845-853
• 174 Robinson SM, Wilson CH, Burt AD et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012; 19: 4287-4299
• 175 Bower M, Wunderlich C, Brown R et al. Obesity rather than neoadjuvant chemotherapy predicts steatohepatitis in patients with colorectal metastasis. Am J Surg 2013; 205: 685-690
• 176 Ryan P, Nanji S, Pollett A et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010; 34: 784-791
• 177 Kotronen A, Westerbacka J, Bergholm R et al. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490-3497
• 178 Lee SS, Park SH, Kim HJ et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010; 52: 579-585
• 179 Leite NC, Salles GF, Araujo AL et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119
• 180 de Lédinghen V, Ratziu V, Causse X et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 2006; 45: 592-599
• 181 Soderberg C, Stal P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602
• 182 Santoro N, Kursawe R, D'Adamo E et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52: 1281-1290
• 183 Shen J, Wong GL, Chan HL et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014; 39: 532-539
• 184 Johnson PC, Logue J, McConnachie A et al. Intergenerational change and familial aggregation of body mass index. Eur J Epidemiol 2012; 27: 53-61
• 185 Robl M, Knerr I, Keller KM et al. Obesity in children and adolescents and their parents. Correlation of standardized body mass index between patients, their parents and siblings from the multicentre APS data. Dtsch Med Wochenschr 2008; 133: 2448-2453
• 186 Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967
• 187 Kim D, Kim WR, Kim HJ et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365
• 188 Makadia SS, Blaha M, Keenan T et al. Relation of hepatic steatosis to atherogenic dyslipidemia. Am J Cardiol 2013; 112: 1599-1604
• 189 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344
• 190 Choi JH, Rhee EJ, Bae JC et al. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res 2013; 44: 115-120
• 191 Peng XE, Chen FL, Wu YL et al. The roles of HBV infection and host factors in ultrasound-diagnosed fatty liver: a case-control study. Hepatogastroenterology 2013; 60: 1698-1704
• 192 Zelber-Sagi S, Lotan R, Shibolet O et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 2013; 33: 1406-1412
• 193 Sanyal AJ, Brunt EM, Kleiner DE et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353
• 194 Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117
• 195 Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 1947-1954
• 196 Dunn W, Sanyal AJ, Brunt EM et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57: 384-391
• 197 Sookoian S, Castano GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut 2014; 63: 530-532
• 198 Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 2001; 47: 13-27
• 199 Jatlow PI, Agro A, Wu R et al. Ethyl glucuronide and ethyl sulfate assays in clinical trials, interpretation, and limitations: results of a dose ranging alcohol challenge study and 2 clinical trials. Alcohol Clin Exp Res 2014; 38: 2056-2065
• 200 Kowdley KV. The role of iron in nonalcoholic fatty liver disease: the story continues. Gastroenterology 2010; 138: 817-819
• 201 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-317
• 202 Bacon BR, Adams PC, Kowdley KV et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328-343
• 203 Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642
• 204 Lonardo A, Adinolfi LE, Loria P et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-597
• 205 Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-3043
• 206 Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-1364
• 207 Castera L, Hezode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-424
• 208 Hezode C, Roudot-Thoraval F, Zafrani ES et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-458
• 209 Kawaguchi T, Ide T, Taniguchi E et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-576
• 210 Kumar D, Farrell GC, Fung C et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-1272
• 211 Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterol Hepatol (NY) 2012; 8: 305-312
• 212 Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-490
• 213 Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol 2013; 47: 182-187
• 214 Abenavoli L, Milic N, De Lorenzo A et al. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013; 43: 65-67
• 215 Grieco A, Miele L, Pignatoro G et al. Is coeliac disease a confounding factor in the diagnosis of NASH?. Gut 2001; 49: 596
• 216 Kalsch J, Bechmann LP, Manka P et al. Non-alcoholic steatohepatitis occurs in celiac disease and is associated with cellular stress. Z Gastroenterol 2013; 51: 26-31
• 217 Xu ZW, Li YS. Pathogenesis and treatment of parenteral nutrition-associated liver disease. Hepatobiliary Pancreat Dis Int 2012; 11: 586-593
• 218 Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J Med 2009; 361: 1088-1097
• 219 Akpinar E, Akhan O. Liver imaging findings of Wilson's disease. Eur J Radiol 2007; 61: 25-32
• 220 Kuloglu Z, Kansu A, Demirceken F et al. An unusual presentation of Wilson's disease in childhood: nodular fatty infiltration in liver. Turk J Pediatr 2008; 50: 167-170
• 221 Mahmood S, Inada N, Izumi A et al. Wilson's disease masquerading as nonalcoholic steatohepatitis. N Am J Med Sci 2009; 1: 74-76
• 222 Merle U, Schaefer M, Ferenci P et al. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 2007; 56: 115-120
• 223 Hautekeete ML, Degott C, Benhamou JP. Microvesicular steatosis of the liver. Acta Clin Belg 1990; 45: 311-326
• 224 Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115: 141-150
• 225 Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev 2008; 29: 939-960
• 226 Fromenty B. Drug-induced liver injury in obesity. J Hepatol 2013; 58: 824-826
• 227 vom Dahl S, Harzer K, Rolfs A et al. Hepatosplenomegalic lipidosis: what unless Gaucher? Adult cholesteryl ester storage disease (CESD) with anemia, mesenteric lipodystrophy, increased plasma chitotriosidase activity and a homozygous lysosomal acid lipase -1 exon 8 splice junction mutation. J Hepatol 1999; 31: 741-746
• 228 Safar ZE, Lungu AO, Cochran EK et al. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013; 59: 131-137
• 229 Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol 2014; 25: 161-168
• 230 Andersen T, Gluud C, Franzmann MB et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991; 12: 224-229
• 231 Luyckx FH, Desaive C, Thiry A et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226
• 232 Glasgow JF, Middleton B. Reye syndrome – insights on causation and prognosis. Arch Dis Child 2001; 85: 351-353
• 233 Monto AS. The disappearance of Reye's syndrome – a public health triumph. N Engl J Med 1999; 340: 1423-1424
• 234 Wood C. Reye's syndrome. Round Table Series 8. 1 ed. London: Royal Society of Medicine Services; 1988: 153-154
• 235 Ahmed KT, Almashhrawi AA, Rahman RN et al. Liver diseases in pregnancy: diseases unique to pregnancy. World J Gastroenterol 2013; 19: 7639-7646
• 236 Knox TA, Olans LB. Liver disease in pregnancy. N Engl J Med 1996; 335: 569-576
• 237 Arias F, Mancilla-Jimenez R. Hepatic fibrinogen deposits in pre-eclampsia. Immunofluorescent evidence. N Engl J Med 1976; 295: 578-582
• 238 Greten TF, Malek NP, Schmidt S et al. Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 2013; 51: 1269-1326
• 239 Iwasaki M, Takada Y, Hayashi M et al. Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation 2004; 78: 1501-1505
• 240 Tang A, Tan J, Sun M et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 2013; 267: 422-431
• 241 Cowin GJ, Jonsson JR, Bauer JD et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008; 28: 937-945
• 242 Machann J, Thamer C, Schnoedt B et al. Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med 2006; 55: 913-917
• 243 Bastati N, Feier D, Wibmer A et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 2014; 271: 739-747
• 244 Ding Y, Rao SX, Meng T et al. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol 2014; 24: 959-966
• 245 Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 691-701
• 246 Le RT, Llopis M, Lepage P et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62: 1787-1794
• 247 Yoshimoto S, Loo TM, Atarashi K et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97-101
• 248 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-675
• 249 Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023
• 250 Frieser M, Lindner A, Meyer S et al. Spectrum and bleeding complications of sonographically guided interventions of the liver and pancreas. Ultraschall Med 2009; 30: 168-174
• 251 Janiec DJ, Jacobson ER, Freeth A et al. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg 2005; 15: 497-501
• 252 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20: 475-485
• 253 Vuppalanchi R, Unalp A, Van Natta ML et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 481-486
• 254 Denzer U, Arnoldy A, Kanzler S et al. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol 2007; 41: 103-110
• 255 Pfeifer L, Goertz RS, Sturm J et al. Acoustic radiation force impulse (ARFI) and high-frequency ultrasound of the liver surface for the diagnosis of compensated liver cirrhosis. Ultraschall Med 2014; 35: 44-50
• 256 Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618
• 257 Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33
• 258 Koehler EM, Schouten JN, Hansen BE et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol 2013; 11: 1201-1204
• 259 Munteanu M, Ratziu V, Morra R et al. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis 2008; 17: 187-191
• 260 Poynard T, Ratziu V, Naveau S et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10
• 261 Poynard T, Lassailly G, Diaz E et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One 2012; 7: e30325
• 262 Shi KQ, Tang JZ, Zhu XL et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 2014; 29: 1149-1158
• 263 Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2014; 29: 1470-1476
• 264 Kumar M, Rastogi A, Singh T et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?. J Gastroenterol Hepatol 2013; 28: 1194-1201
• 265 de Lédinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 2014; 60: 1026-1031
• 266 Kwok R, Tse YK, Wong GL et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease – the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-269
• 267 Chen J, Zhu Y, Zheng Q et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res 2014; 44: 854-862
• 268 Cusi K, Chang Z, Harrison S et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014; 60: 167-174
• 269 Anty R, Iannelli A, Patouraux S et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 2010; 32: 1315-1322
• 270 Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18: 1430-1437
• 271 Younossi ZM, Page S, Rafiq N et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21: 431-439
• 272 Poynard T, Ratziu V, Charlotte F et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 34
• 273 Tanwar S, Trembling PM, Guha IN et al. Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. Hepatology 2013; 57: 103-111
• 274 Campos GM, Bambha K, Vittinghoff E et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008; 47: 1916-1923
• 275 Sumida Y, Yoneda M, Hyogo H et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-268
• 276 Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974
• 277 Stebbing J, Farouk L, Panos G et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-219
• 278 Talwalkar JA, Kurtz DM, Schoenleber SJ et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-1220
• 279 Tsochatzis EA, Gurusamy KS, Ntaoula S et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659
• 280 Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104
• 281 Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-462
• 282 Gaia S, Carenzi S, Barilli AL et al. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64-71
• 283 Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208
• 284 Petta S, Di Marco V, Camma C et al. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011; 33: 1350-1360
• 285 Wong VW, Vergniol J, Wong GL et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-1871
• 286 Castera L, Foucher J, Bernard PH et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835
• 287 Wong GL, Vergniol J, Lo P et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan(R)): applying the cut-offs of M probe to XL probe. Ann Hepatol 2013; 12: 570-580
• 288 Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-e219
• 289 Nierhoff J, Chavez Ortiz AA, Herrmann E et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol 2013; 23: 3040-3053
• 290 Fierbinteanu BC, Sporea I, Panaitescu E et al. Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease. Ultrasound Med Biol 2013; 39: 1942-1950
• 291 Friedrich-Rust M, Romen D, Vermehren J et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-e331
• 292 Palmeri ML, Wang MH, Rouze NC et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-672
• 293 Yoneda M, Suzuki K, Kato S et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-647
• 294 Ferraioli G, Tinelli C, Dal BB et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. Hepatology 2012; 56: 2125-2133
• 295 Leung VY, Shen J, Wong VW et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology 2013; 269: 910-918
• 296 Ma JJ, Ding H, Mao F et al. Assessment of liver fibrosis with elastography point quantification technique in chronic hepatitis B virus patients: a comparison with liver pathological results. J Gastroenterol Hepatol 2014; 29: 814-819
• 297 Ochi H, Hirooka M, Koizumi Y et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56: 1271-1278
• 298 Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460
• 299 Ratziu V, Massard J, Charlotte F et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6
• 300 Kumar R, Rastogi A, Sharma MK et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013; 58: 265-274
• 301 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540
• 302 Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 49-73
• 303 Keil U, Fitzgerald AP, Gohlke H et al. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen: Die neuen SCORE-Deutschland-Tabellen für die Primärprävention. Dtsch Arztebl 2005; 102 : A-1808/B-1526/C-1441
• 304 Colak Y, Senates E, Yesil A et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013; 43: 100-107
• 305 Dogru T, Genc H, Tapan S et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease?. Diabetes Res Clin Pract 2012; 96: 47-52
• 306 Vlachopoulos C, Manesis E, Baou K et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010; 23: 1183-1189
• 307 Touboul PJ, Hennerici MG, Meairs S et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007; 23: 75-80
• 308 Mayer-Berger W, Simic D, Mahmoodzad J et al. Efficacy of a long-term secondary prevention programme following inpatient cardiovascular rehabilitation on risk and health-related quality of life in a low-education cohort: a randomized controlled study. Eur J Prev Cardiol 2014; 21: 145-152
• 309 Kozakova M, Palombo C, Eng MP et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology 2012; 55: 1406-1415
• 310 Goff Jr DC , Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S49-S73
• 311 Yeboah J, McClelland RL, Polonsky TS et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788-795
• 312 Oni ET, Agatston AS, Blaha MJ et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?. Atherosclerosis 2013; 230: 258-267
• 313 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
• 314 http://www.dgvs.de/fileadmin/user_upload/Leitlinien/richtlinien-empfehlungen/2.3.Oesophagusvarizen.pdf
• 315 Garcia-Tsao G, Sanyal AJ, Grace ND et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Am J Gastroenterol 2007; 102: 2086-2102
• 316 Wieland AC, Quallick M, Truesdale A et al. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci 2013; 58: 2809-2816
• 317 Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873
• 318 Salas-Salvado J, Bullo M, Estruch R et al. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial. Ann Intern Med 2014; 160: 1-10
• 319 Babio N, Toledo E, Estruch R et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial. CMAJ 2014; 186: E649-E657
• 320 Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087
• 321 Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 2008; 48: 1791-1798
• 322 Kistler KD, Brunt EM, Clark JM et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 2011; 106: 460-468
• 323 Koopman KE, Caan MW, Nederveen AJ et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Hepatology 2014; 60: 545-553
• 324 Malik VS, Popkin BM, Bray GA et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care 2010; 33: 2477-2483
• 325 Te ML, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 2013; 346: e7492
• 326 Walker RW, Le KA, Davis J et al. High rates of fructose malabsorption are associated with reduced liver fat in obese African Americans. J Am Coll Nutr 2012; 31: 369-374
• 327 Davis JN, Le KA, Walker RW et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010; 92: 1522-1527
• 328 Te Morenga LA, Howatson AJ, Jones RM et al. Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids. Am J Clin Nutr 2014; 100: 65-79
• 329 Yang Q, Zhang Z, Gregg EW et al. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med 2014; 174: 516-524
• 330 Johnson RK, Appel LJ, Brands M et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 2009; 120: 1011-1020
• 331 Hoofnagle JH, Van Natta ML, Kleiner DE et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2013; 38: 134-143
• 332 De Luis DA, Gonzalez SM, Aller R et al. Effects of C358A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase on weight loss after a hypocaloric diet. Metabolism 2011; 60: 730-734
• 333 Elias MC, Parise ER, de Carvalho L et al. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 2010; 26: 1094-1099
• 334 Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072-1081
• 335 Utzschneider KM, Bayer-Carter JL, Arbuckle MD et al. Beneficial effect of a weight-stable, low-fat/low-saturated fat/low-glycaemic index diet to reduce liver fat in older subjects. Br J Nutr 2013; 109: 1096-1104
• 336 Sofi F, Giangrandi I, Cesari F et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010; 61: 792-802
• 337 Malaguarnera M, Gargante MP, Russo C et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis – a randomized and controlled clinical trial. Am J Gastroenterol 2010; 105: 1338-1345
• 338 Ryan MC, Itsiopoulos C, Thodis T et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59: 138-143
• 339 Bacchi E, Negri C, Targher G et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology 2013; 58: 1287-1295
• 340 Hallsworth K, Fattakhova G, Hollingsworth KG et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 2011; 60: 1278-1283
• 341 Shah K, Stufflebam A, Hilton TN et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009; 17: 2162-2168
• 342 Burza MA, Romeo S, Kotronen A et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One 2013; 8: e60495
• 343 Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006; 16: 1278-1286
• 344 Stratopoulos C, Papakonstantinou A, Terzis I et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005; 15: 1154-1160
• 345 Abidov M, Ramazanov Z, Seifulla R et al. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 2010; 12: 72-81
• 346 Alisi A, Bedogni G, Baviera G et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39: 1276-1285
• 347 Aller R, De Luis DA, Izaola O et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011; 15: 1090-1095
• 348 Illnait J, Rodriguez I, Mendoza S et al. Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean J Intern Med 2013; 28: 439-448
• 349 Li L, Zhang XJ, Lan Y et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med 2010; 16: 23-27
• 350 Ma YY, Li L, Yu CH et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2013; 19: 6911-6918
• 351 Garinis GA, Fruci B, Mazza A et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010; 34: 1255-1264
• 352 Krakoff J, Clark JM, Crandall JP et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010; 18: 1762-1767
• 353 Resuli B, Demiraj V, Babameto A et al. Metformin superior to lowfat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis. Pol Arch Med Wewn 2012; 122 (Suppl. 01) 68-71
• 354 Saryusz-Wolska M, Szymanska-Garbacz E, Jablkowski M et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn 2011; 121: 61-66
• 355 Harrison SA, Fecht W, Brunt EM et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009; 49: 80-86
• 356 Cichoz-Lach H, Celinski K, Konturek PC et al. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol 2010; 61: 577-580
• 357 Gonciarz M, Gonciarz Z, Bielanski W et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40
• 358 Chan DC, Watts GF, Gan SK et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-1139
• 359 Ratziu V, de Ledinghen V, Oberti F et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011; 54: 1011-1019
• 360 Mudaliar S, Henry RR, Sanyal AJ et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582
• 361 Safadi R, Konikoff FM, Mahamid M et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2085-2091
• 362 Vilar GE, Rodriguez De Miranda A, Gra OB et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009; 30: 999-1009
• 363 Loguercio C, Andreone P, Brisc C et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med 2012; 52: 1658-1665
• 364 Malaguarnera M, Vacante M, Antic T et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci 2012; 57: 545-553
• 365 Torres DM, Jones FJ, Shaw JC et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial. Hepatology 2011; 54: 1631-1639
• 366 Park H, Shima T, Yamaguchi K et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-107
• 367 Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011; 54: 1610-1619
• 368 Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50: 1818-1826
• 369 Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol 2013; 10: 676-685
• 370 Kim D, Choi SY, Park EH et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613
• 371 Wong VW, Wong GL, Yip GW et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-1727
• 372 Kim NH, Park J, Kim SH et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100: 938-943
• 373 Pugh CJ, Cuthbertson DJ, Sprung VS et al. Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2013; 305: E50-E58
• 374 Shargorodsky M, Omelchenko E, Matas Z et al. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovasc Diabetol 2012; 11: 61
• 375 Sofer E, Boaz M, Matas Z et al. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 2011; 60: 1278-1284
• 376 Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-266
• 377 Keating SE, Hackett DA, George J et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 57: 157-166
• 378 Musso G, Cassader M, Rosina F et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012; 55: 885-904
• 379 Promrat K, Kleiner DE, Niemeier HM et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-129
• 380 Plauth M, Schütz T, Pirlich M et al. S3-Leitlinie DGEM. Aktuel Ernährungsmed 2014; 39: e1-e42
• 381 Garcia-Pagan JC, Santos C, Barbera JA et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996; 111: 1300-1306
• 382 Bandi JC, Garcia-Pagan JC, Escorsell A et al. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology 1998; 28: 677-682
• 383 Roman E, Torrades MT, Nadal MJ et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Dig Dis Sci 2014; 59: 1966-1975
• 384 Zenith L, Meena N, Ramadi A et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 1920-1926
• 385 Deibert P, Konig D, Allgaier HP et al. Sport and the digestive system. Dtsch Med Wochenschr 2007; 132: 155-160
• 386 Felber J, Aust D, Baas S et al. Results of a S2k-Consensus Conference of the German Society of Gastroenterolgy, Digestive- and Metabolic Diseases (DGVS) in conjunction with the German Coeliac Society (DZG) regarding coeliac disease, wheat allergy and wheat sensitivity. Z Gastroenterol 2014; 52: 711-743
• 387 Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290
• 388 Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S76-S99
• 389 Mente A, O'Donnell MJ, Rangarajan S et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med 2014; 371: 601-611
• 390 O'Donnell M, Mente A, Rangarajan S et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 2014; 371: 612-623
• 391 Oparil S. Low sodium intake – cardiovascular health benefit or risk?. N Engl J Med 2014; 371: 677-679
• 392 Harrison SA, Torgerson S, Hayashi P et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490
• 393 Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540
• 394 Miller III ER, Pastor-Barriuso R, Dalal D et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46
• 395 Xiang Z, Chen YP, Ma KF et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140
• 396 Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-965
• 397 http://www.hochdruckliga.de/tl_files/content/dhl/downloads/2014_Pocket-Leitlinien_Arterielle_Hypertonie.pdf
• 398 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
• 399 James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
• 400 Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
• 401 Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
• 402 Stone NJ, Robinson JG, Lichtenstein AH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-S45
• 403 Caiazzo R, Lassailly G, Leteurtre E et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 2014; 260: 893-898
• 404 Cazzo E, Jimenez LS, Pareja JC et al. Effect of Roux-en-y Gastric Bypass on Nonalcoholic Fatty Liver Disease Evaluated Through NAFLD Fibrosis Score: a Prospective Study. Obes Surg 2015; 25: 982-985
• 405 de Jonge C, Rensen SS, Koek GH et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013; 11: 1517-1520
• 406 Elnahas A, Nguyen GC, Okrainec A et al. The effect of underlying liver disease on short-term outcomes following bariatric surgery. Surg Endosc 2014; 28: 2708-2712
• 407 Runkel N, Colombo-Benkmann M, Huttl TP et al. Evidence-based German guidelines for surgery for obesity. Int J Colorectal Dis 2011; 26: 397-404
• 408 Schauer PR, Kashyap SR, Wolski K et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576
• 409 Glass LM, Dickson RC, Anderson JC et al. Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci 2015; 60: 1024-1030
• 410 Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575-1584
• 411 Vinje S, Stroes E, Nieuwdorp M et al. The gut microbiome as novel cardio-metabolic target: the time has come!. Eur Heart J 2014; 35: 883-887
• 412 Fei N, Zhao L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J 2013; 7: 880-884
• 413 Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916
• 414 Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693
• 415 Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
• 416 Sjostrom L, Peltonen M, Jacobson P et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65
• 417 Gloy VL, Briel M, Bhatt DL et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 347: f5934
• 418 Jayasekara H, English DR, Room R et al. Alcohol consumption over time and risk of death: a systematic review and meta-analysis. Am J Epidemiol 2014; 179: 1049-1059
• 419 Loomba R, Bettencourt R, Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: the Rancho Bernardo Study. Aliment Pharmacol Ther 2009; 30: 1137-1149
• 420 Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005; 3: 1260-1268
• 421 Cotrim HP, Freitas LA, Alves E et al. Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur J Gastroenterol Hepatol 2009; 21: 969-972
• 422 Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100
• 423 Kwon HK, Greenson JK, Conjeevaram HS. Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease. Liver Int 2014; 34: 129-135
• 424 Ekstedt M, Franzen LE, Holmqvist M et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44: 366-374
• 425 Gabele E, Dostert K, Dorn C et al. A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. Alcohol Clin Exp Res 2011; 35: 1361-1367
• 426 Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use?. Am J Gastroenterol 2012; 107: 976-978
• 427 Linhart KB, Glassen K, Peccerella T et al. The generation of carcinogenic etheno DNA adducts in the liver of patients with NAFLD. Hepatobil Surg Nutr (in press) 2015;
• 428 Nascimento AF, Ip BC, Luvizotto RA et al. Aggravation of nonalcoholic steatohepatitis by moderate alcohol consumption is associated with decreased SIRT1 activity in rats. Hepatobiliary Surg Nutr 2013; 2: 252-259
• 429 Wang Y, Millonig G, Nair J et al. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology 2009; 50: 453-461
• 430 Wang Y, Seitz HK, Wang XD. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin Exp Res 2010; 34: 567-573
• 431 Xu J, Lai KK, Verlinsky A et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol 2011; 55: 673-682
• 432 Saab S, Mallam D, Cox GA et al. Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504
• 433 Birerdinc A, Stepanova M, Pawloski L et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 76-82
• 434 Anty R, Marjoux S, Iannelli A et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090-1096
• 435 Poikolainen K, Vartiainen E. Determinants of gamma-glutamyltransferase: positive interaction with alcohol and body mass index, negative association with coffee. Am J Epidemiol 1997; 146: 1019-1024
• 436 Ding M, Bhupathiraju SN, Satija A et al. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014; 129: 643-659
• 437 Xiao Q, Sinha R, Graubard BI et al. Inverse associations of total and decaffeinated coffee with liver enzyme levels in National Health and Nutrition Examination Survey 1999-2010. Hepatology 2014; 60: 2091-2098
• 438 Pessione F, Ramond MJ, Njapoum C et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34: 121-125
• 439 Zein CO, Beatty K, Post AB et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006; 44: 1564-1571
• 440 Liu Y, Dai M, Bi Y et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. J Epidemiol 2013; 23: 115-121
• 441 Zheng RD, Chen JN, Zhuang QY et al. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci 2013; 10: 641-646
• 442 Cornberg M, Protzer U, Petersen J et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection – the German guideline. Z Gastroenterol 2011; 49: 871-930
• 443 Chalasani N, Aljadhey H, Kesterson J et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-1292
• 444 Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695
• 445 Abel T, Feher J, Dinya E et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-MS11
• 446 Kimura Y, Hyogo H, Yamagishi S et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757
• 447 Schramm C, Dinter J, Demir M et al. Hypertonie-Prävalenz und antihypertensive Behandlungsmodalitäten bei Patienten mit bioptisch gesicherter nicht-alkoholischer Fettlebererkrankung. J Hyperton 2010; 14: 21-25
• 448 Töx U, Steffen HM. Impact of inhibitors of the Renin-Angiotensin-aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem 2006; 13: 3649-3661
• 449 Georgescu EF, Ionescu R, Niculescu M et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-954
• 450 http://www.akdae.de/Arzneimittelsicherheit/Bekanntgaben/Archiv/2013/20130308.html
• 451 Li Y, Liu L, Wang B et al. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2013; 1: 57-64
• 452 Zhang X, Harmsen WS, Mettler TA et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60: 2008-2016
• 453 Zhang H, Gao C, Fang L et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78-87
• 454 Schmiedl S, Rottenkolber M, Szymanski J et al. Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments. Dtsch Arztebl Int 2013; 110: 244-252
• 455 Lisman T, Kamphuisen PW, Northup PG et al. Established and new-generation antithrombotic drugs in patients with cirrhosis – possibilities and caveats. J Hepatol 2013; 59: 358-366
• 456 http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/34_14.pdf
• 457 Heuer M, Kaiser GM, Kahraman A et al. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012; 86: 107-113
• 458 LaMattina JC, Foley DP, Fernandez LA et al. Complications associated with liver transplantation in the obese recipient. Clin Transplant 2012; 26: 910-918
• 459 Heimbach JK, Watt KD, Poterucha JJ et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13: 363-368
• 460 Rowe IA, Webb K, Gunson BK et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008; 21: 459-465
• 461 Sebagh M, Samuel D, Antonini TM et al. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol 2012; 56: 840-847
• 462 Yalamanchili K, Saadeh S, Klintmalm GB et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16: 431-439
• 463 Dumortier J, Giostra E, Belbouab S et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 2010; 105: 613-620
• 464 Schutz T, Hudjetz H, Roske AE et al. Weight gain in long-term survivors of kidney or liver transplantation – another paradigm of sarcopenic obesity?. Nutrition 2012; 28: 378-383
• 465 Chavin KD, Taber DJ, Norcross M et al. Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm. Clin Transplant 2013; 27: 732-741
• 466 Gabrielli M, Moisan F, Vidal M et al. Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. Ann Hepatol 2012; 11: 891-898
• 467 Oshita A, Tashiro H, Amano H et al. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. Transplantation 2012; 93: 1024-1030
• 468 Reddy SK, Marsh JW, Varley PR et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology 2012; 56: 2221-2230
• 469 Sydor S, Gu Y, Schlattjan M et al. Steatosis does not impair liver regeneration after partial hepatectomy. Lab Invest 2013; 93: 20-30
• 470 van der Poorten D, Samer CF, Ramezani-Moghadam M et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause?. Hepatology 2013; 57: 2180-2188
• 471 Bechmann LP, Kocabayoglu P, Sowa JP et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013; 57: 1394-1406
• 472 Collin de l'Hortet A, Zerrad-Saadi A, Prip-Buus C et al. GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. Endocrinology 2014; 155: 2545-2554
• 473 Jimenez-Castro MB, Casillas-Ramirez A, Mendes-Braz M et al. Adiponectin and resistin protect steatotic livers undergoing transplantation. J Hepatol 2013; 59: 1208-1214
• 474 Wedemeyer I, Bechmann LP, Odenthal M et al. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-149
• 475 Kennedy C, Redden D, Gray S et al. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford) 2012; 14: 625-634
• 476 Agopian VG, Kaldas FM, Hong JC et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012; 256: 624-633
• 477 VanWagner LB, Bhave M, Te HS et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56: 1741-1750
• 478 Wang X, Li J, Riaz DR et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 394-402
• 479 Malik SM, deVera ME, Fontes P et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9: 782-793
• 480 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011; 26: 1361-1367
• 481 Wong VW, Wong GL, Chu WC et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012; 56: 533-540
• 482 Peng D, Han Y, Ding H et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23: 1082-1088
• 483 Lim YS, Han S, Heo NY et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014; 147: 152-161
• 484 Petta S, Camma C, Di Marco V et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int 2011; 31: 507-515
• 485 Zheng RD, Xu CR, Jiang L et al. Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci 2010; 7: 272-277
• 486 Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?. Int J Obes (Lond) 2007; 31: 871-875
• 487 Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007; 41: 513-517
• 488 Marcellin P, Gane E, Buti M et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475
• 489 Vespasiani-Gentilucci U, Gallo P, De Vincentis A et al. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol 2014; 20: 2825-2838
• 490 Roingeard P. Hepatitis C virus diversity and hepatic steatosis. J Viral Hepat 2013; 20: 77-84
• 491 Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter?. J Hepatol 2012; 56 (Suppl. 01) S56-S65
• 492 Petta S, Marchesini G, Caracausi L et al. Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol 2013; 59: 1169-1176
• 493 Dunn W, O'Neil M, Zhao J et al. Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology 2014; 59: 453-460
• 494 Stattermayer AF, Scherzer T, Beinhardt S et al. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014; 39: 1059-1070
• 495 Cross TJ, Quaglia A, Hughes S et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat 2009; 16: 492-499
• 496 Garcia-Monzon C, Lo IO, Mayoral R et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol 2011; 54: 142-152
• 497 Moucari R, Asselah T, Cazals-Hatem D et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-423
• 498 Nieminen U, Arkkila PE, Karkkainen P et al. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. Liver Int 2009; 29: 153-158
• 499 Pekow JR, Bhan AK, Zheng H et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007; 109: 2490-2496
• 500 Takuma Y, Nouso K, Makino Y et al. Hepatic steatosis correlates with the postoperative recurrence of hepatitis C virus-associated hepatocellular carcinoma. Liver Int 2007; 27: 620-626
• 501 Tanaka A, Uegaki S, Kurihara H et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-5187
• 502 Adinolfi LE, Restivo L, Zampino R et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221: 496-502
• 503 Brandman D, Pingitore A, Lai JC et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380-1386
• 504 Briceno J, Ciria R, Pleguezuelo M et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48
• 505 Yilmaz N, Shiffman ML, Stravitz RT et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975-983
• 506 Aziz H, Gill U, Raza A et al. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients. Eur J Gastroenterol Hepatol 2014; 26: 538-543
• 507 Grasso A, Malfatti F, De Leo P et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984-990
• 508 Guedj H, Guedj J, Negro F et al. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 2012; 19: 488-496
• 509 Moucari R, Ripault MP, Martinot-Peignoux M et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-1669
• 510 Shah SR, Patel K, Marcellin P et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011; 9: 688-693
• 511 Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85
• 512 Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887
• 513 Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888
• 514 Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603
• 515 Vuppalanchi R, Gould RJ, Wilson LA et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012; 6: 379-385
• 516 Cotler SJ, Kanji K, Keshavarzian A et al. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004; 38: 801-804
• 517 Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004; 99: 1316-1320
• 518 Tsuneyama K, Baba H, Kikuchi K et al. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol 2013; 45: 143-148
• 519 Niwa H, Sasaki M, Haratake J et al. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 923-931
• 520 Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 2173-2181
• 521 Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci 2011; 56: 3421-3438
• 522 Czaja AJ. Autoantibody-negative autoimmune hepatitis. Dig Dis Sci 2012; 57: 610-624
• 523 Chowdhary VR, Crowson CS, Poterucha JJ et al. Liver involvement in systemic lupus erythematosus: case review of 40 patients. J Rheumatol 2008; 35: 2159-2164
• 524 Freeman HJ. Hepatic manifestations of celiac disease. Clin Exp Gastroenterol 2010; 3: 33-39
• 525 Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002; 35: 345-349
• 526 Gatselis NK, Zachou K, Papamichalis P et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score?. Dig Liver Dis 2010; 42: 807-812
• 527 Papamichalis PA, Zachou K, Koukoulis GK et al. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis 2007; 4: 3
• 528 Yatsuji S, Hashimoto E, Kaneda H et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful?. J Gastroenterol 2005; 40: 1130-1138
• 529 Kanda T, Yokosuka O, Imazeki F et al. Body mass index in Japanese patients with autoimmune liver disease: overweight patients with primary biliary cirrhosis tend to be asymptomatic. Hepatogastroenterology 2007; 54: 1758-1760
• 530 Sorrentino P, Terracciano L, D'Angelo S et al. Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010; 45: 1053-1062
• 531 Hindi M, Levy C, Couto CA et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol 2013; 47: e28-e32
• 532 Ludvigsson JF, Bergquist A, Montgomery SM et al. Risk of diabetes and cardiovascular disease in patients with primary sclerosing cholangitis. J Hepatol 2014; 60: 802-808
• 533 Powell EE, Ali A, Clouston AD et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005; 129: 1937-1943
• 534 Adams LA, Angulo P, Abraham SC et al. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int 2006; 26: 298-304
• 535 Wood MJ, Powell LW, Dixon JL et al. Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus. Hepatology 2012; 56: 904-911
• 536 Chandok N, Minuk G, Wengiel M et al. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2012; 21: 53-58
• 537 Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77-85
• 538 Yoneda M, Thomas E, Sumida Y et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. Hepatol Res 2014; 44: E499-E502
• 539 Fracanzani AL, Valenti L, Russello M et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One 2012; 7: e41183
• 540 Koller T, Kollerova J, Hlavaty T et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol 2012; 47: 197-203
• 541 Loria P, Lonardo A, Lombardini S et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol 2005; 20: 1176-1184
• 542 Chen JY, Hsu CT, Liu JH et al. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol 2014; 14: 83
• 543 Stokes CS, Gluud LL, Casper M et al. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2014; 12: 1090-1100
• 544 Price JC, Thio CL. Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 2010; 8: 1002-1012
• 545 Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52: 71-78
• 546 Price JC, Seaberg EC, Latanich R et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol 2014; 109: 695-704
• 547 Nishijima T, Gatanaga H, Shimbo T et al. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS One 2014; 9: e87596
• 548 Borghi V, Bisi L, Manzini L et al. Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. Infection 2013; 41: 425-429
• 549 Sulkowski MS, Mehta SH, Torbenson M et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592
• 550 Kahraman A, Miller M, Gieseler RK et al. Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases. Eur J Gastroenterol Hepatol 2006; 18: 101-105
• 551 Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev 2007; 16: 2533-2547
• 552 Hwang ST, Cho YK, Park JH et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010; 25: 562-567
• 553 Wong VW, Wong GL, Tsang SW et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836
• 554 Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol 2012; 27: 91-95
• 555 Stadlmayr A, Aigner E, Steger B et al. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med 2011; 270: 41-49
• 556 Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 2011; 43: 317-334
• 557 Tarantino G, Saldalamacchia G, Conca P et al. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303
• 558 Myers RP, Shaheen AA. Hepatitis C, alcohol abuse, and unintentional overdoses are risk factors for acetaminophen-related hepatotoxicity. Hepatology 2009; 49: 1399-1400
• 559 Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008; 48: 1336-1341
• 560 Forget P, Wittebole X, Laterre PF. Therapeutic dose of acetaminophen may induce fulminant hepatitis in the presence of risk factors: a report of two cases. Br J Anaesth 2009; 103: 899-900
• 561 Masia R, Pratt DS, Misdraji J. A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease. Arch Pathol Lab Med 2012; 136: 618-622
• 562 Rojas-Feria M, Castro M, Suarez E et al. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol 2013; 19: 7327-7340
• 563 Pagadala M, Dasarathy S, Eghtesad B et al. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670
• 564 Pinto LF, Compri CM, Fornari JV et al. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 2010; 30: 603-610
• 565 Patsenker E, Schneider V, Ledermann M et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-398
• 566 Sourianarayanane A, Garg G, Smith TH et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7: e279-e285
• 567 Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-1544
• 568 Denzer C, Thiere D, Muche R et al. Gender-specific prevalences of fatty liver in obese children and adolescents: roles of body fat distribution, sex steroids, and insulin resistance. J Clin Endocrinol Metab 2009; 94: 3872-3881
• 569 Eng K, Lopez R, Liccardo D et al. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Dig Liver Dis 2014; 46: 1008-1013
• 570 Molleston JP, White F, Teckman J et al. Obese children with steatohepatitis can develop cirrhosis in childhood. Am J Gastroenterol 2002; 97: 2460-2462
• 571 Vajro P, Lenta S, Socha P et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012; 54: 700-713
• 572 Baumann U. Differenzialdiagnostik bei persistierender Erhöhung derTransaminasenkonzentrationen – KlinischeEinschätzung und Vorgehen. Monatsschr Kinderheilkd 2015; 163: 167-178
• 573 Nobili V, Alkhouri N, Alisi A et al. Nonalcoholic Fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169: 170-176